Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Matthew C Hiemenz"'
Autor:
Douglas I. Lin, Julia C. F. Quintanilha, Natalie Danziger, Lixin Lang, Diane Levitan, Cynthia Hayne, Matthew C. Hiemenz, David L. Smith, Lee A. Albacker, Jeffrey Leibowitz, Douglas A. Mata, Brennan Decker, Sotirios Lakis, Nimesh R. Patel, Ryon P. Graf, Julia A. Elvin, Jeffrey S. Ross, Varun Pattani, Richard S. P. Huang, Amy K. Wehn
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-9 (2024)
Abstract Microsatellite instability high (MSI-H) and mismatch repair deficient (dMMR) tumor status have been demonstrated to predict patient response to immunotherapies. We developed and validated a next-generation sequencing (NGS)-based companion di
Externí odkaz:
https://doaj.org/article/5b1f54d32e854c9184c1c038f53bf3c6
Autor:
Matthew C Hiemenz, Stephan Kadauke, David B Lieberman, David B Roth, Jianhua Zhao, Christopher D Watt, Robert D Daber, Jennifer J D Morrissette
Publikováno v:
PLoS ONE, Vol 11, Iss 4, p e0152851 (2016)
Next-generation sequencing (NGS) is a powerful platform for identifying cancer mutations. Routine clinical adoption of NGS requires optimized quality control metrics to ensure accurate results. To assess the robustness of our clinical NGS pipeline, w
Externí odkaz:
https://doaj.org/article/443905187da04c1b9c5ac483ee231ef6
Autor:
James J. Pao, Mikayla Biggs, Daniel Duncan, Douglas I. Lin, Richard Davis, Richard S. P. Huang, Donna Ferguson, Tyler Janovitz, Matthew C. Hiemenz, Nathanial R. Eddy, Erik Lehnert, Moran N. Cabili, Garrett M. Frampton, Priti S. Hegde, Lee A. Albacker
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-13 (2023)
Abstract Treatment of non-small cell lung cancer is increasingly biomarker driven with multiple genomic alterations, including those in the epidermal growth factor receptor (EGFR) gene, that benefit from targeted therapies. We developed a set of algo
Externí odkaz:
https://doaj.org/article/7d5e988d3e904b15bcdb8d5cf69259d4
Autor:
Vamsi Parimi, Khaled Tolba, Natalie Danziger, Zheng Kuang, Daokun Sun, Douglas I. Lin, Matthew C. Hiemenz, Alexa B. Schrock, Jeffrey S. Ross, Geoffrey R. Oxnard, Richard S. P. Huang
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-8 (2023)
Abstract In this study, we report the clinicopathologic and genomic profiles of 891 patients with RET fusion driven advanced solid tumors. All patient samples were tested using a tissue-based DNA hybrid capture next generation sequencing (NGS) assay
Externí odkaz:
https://doaj.org/article/91c1ba901dc249f3ae1af6da4be2810e
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Introduction Several studies have shown clinical outcomes data that support the use of CD274 (PD-L1) copy-number (CN) gains and/or losses as a biomarker for immune checkpoint inhibitor (ICPI). Here, we present the landscape of CD274 CN changes across
Externí odkaz:
https://doaj.org/article/c9754252d8e140ad96c8184de22aa3e4
Autor:
Natalie Danziger, Ethan S Sokol, Ryon P Graf, Matthew C Hiemenz, Jake Maule, Vamsi Parimi, Carlo Palmieri, Lajos Pusztai, Jeffrey S Ross, Richard S P Huang
Publikováno v:
The Oncologist. 28:319-326
Background In 2020, pembrolizumab was approved as a therapy for triple-negative breast cancer (TNBC) with the companion diagnostic DAKO 22C3 programmed death ligand-1 (PD-L1) immunohistochemistry assay. The study aimed to determine the landscape of P
Autor:
Richard S P Huang, Lukas Harries, Brennan Decker, Matthew C Hiemenz, Karthikeyan Murugesan, James Creeden, Khaled Tolba, Laura P Stabile, Shakti H Ramkissoon, Timothy F Burns, Jeffrey S Ross
Publikováno v:
The Oncologist. 27:839-848
Background In patients with non-small cell lung cancer (NSCLC), 10%-40% will eventually develop brain metastases. We present the clinicopathologic, genomic, and biomarker landscape of a large cohort of NSCLC brain metastases (NSCLC-BM) samples. Mater
Autor:
Richard S P Huang, Julie Y Tse, Lukas Harries, Ryon P Graf, Douglas I Lin, Karthikeyan Murugesan, Matthew C Hiemenz, Vamsi Parimi, Tyler Janovitz, Brennan Decker, Eric Severson, Mia A Levy, Shakti H Ramkissoon, Julia A Elvin, Jeffrey S Ross, Erik A Williams
Publikováno v:
The Oncologist. 27:655-662
Background In the current study, we examined the real-world prevalence of highly pigmented advanced melanomas (HPMel) and the clinicopathologic, genomic, and ICPI biomarker signatures of this class of tumors. Materials and Methods Our case archive of
Autor:
Matthew C. Hiemenz, Jaspreet Kaur, Zheng Kuang, Richard S. P. Huang, Lukas Harries, Dana Metzger, Kelsie Schiavone, Sherri Z. Millis, Douglas I. Lin, Mirna Lechpammer, Brennan Decker, Douglas A. Mata, Abhinav Reddy, Matthew Parke, Eun Y. Lee, Xiaoyan Cui, O. Hans Iwenofu, Darya Buehler, Les Henderson, Erin M. Baldwin, Sosipatros A. Boikos, Shakti H. Ramkissoon, Steven C. Smith
Publikováno v:
Genes, Chromosomes and Cancer.
Autor:
Hilda Mirbaha, Deyssy Carrillo, Midori Mitui, Matthew C. Hiemenz, Vivekanand Singh, Dinesh Rakheja
Publikováno v:
International Journal of Surgical Pathology. 30:457-461
P53 immunohistochemical staining with antibodies targeted to epitopes at or near the N-terminus are commonly used in diagnostic pathology practice as a surrogate for TP53 mutations. The abnormal staining patterns indicating TP53 mutations include nuc